MX2017004969A - Metodo para tratar el cancer. - Google Patents

Metodo para tratar el cancer.

Info

Publication number
MX2017004969A
MX2017004969A MX2017004969A MX2017004969A MX2017004969A MX 2017004969 A MX2017004969 A MX 2017004969A MX 2017004969 A MX2017004969 A MX 2017004969A MX 2017004969 A MX2017004969 A MX 2017004969A MX 2017004969 A MX2017004969 A MX 2017004969A
Authority
MX
Mexico
Prior art keywords
cell
cancer
subject
ezh2
treating cancer
Prior art date
Application number
MX2017004969A
Other languages
English (en)
Inventor
Keilhack Heike
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of MX2017004969A publication Critical patent/MX2017004969A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un método para tratar o aliviar un síntoma de un trastorno, p. ej., una evasión inmunológica, disfunción inmunológica inducida por células cancerosas, respuesta inmunológica reducida, inflamación reducida, expresión disminuida de un complejo principal de histocompatibilidad (MHC), o cáncer, caracterizado por una actividad y/o expresión aberrante, regulada erróneamente o incrementada del potenciador del Zeste homólogo 2 (EZH2) en una célula o sujeto en necesidad del mismo, poniendo en contacto la célula o administrando al sujeto una cantidad terapéuticamente eficaz de un inhibidor de EZH2.
MX2017004969A 2014-10-16 2015-10-16 Metodo para tratar el cancer. MX2017004969A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064948P 2014-10-16 2014-10-16
US201462065590P 2014-10-17 2014-10-17
PCT/US2015/056022 WO2016061507A1 (en) 2014-10-16 2015-10-16 Method for treating cancer

Publications (1)

Publication Number Publication Date
MX2017004969A true MX2017004969A (es) 2017-07-19

Family

ID=55747431

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021007003A MX2021007003A (es) 2014-10-16 2015-10-16 Método para tratar el cáncer.
MX2017004969A MX2017004969A (es) 2014-10-16 2015-10-16 Metodo para tratar el cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021007003A MX2021007003A (es) 2014-10-16 2015-10-16 Método para tratar el cáncer.

Country Status (13)

Country Link
US (4) US9889138B2 (es)
EP (1) EP3206688A4 (es)
JP (4) JP2017532338A (es)
KR (1) KR102397720B1 (es)
CN (2) CN106794177A (es)
AU (3) AU2015331729A1 (es)
BR (1) BR112017007738B1 (es)
CA (1) CA2963149A1 (es)
EA (1) EA201790845A1 (es)
IL (4) IL310279A (es)
MX (2) MX2021007003A (es)
SG (2) SG10201903356XA (es)
WO (1) WO2016061507A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ746054A (en) * 2012-10-15 2020-07-31 Epizyme Inc Methods of treating cancer
MX2021007003A (es) * 2014-10-16 2022-08-09 Epizyme Inc Método para tratar el cáncer.
AU2015350108B2 (en) 2014-11-17 2021-04-08 Eisai R&D Management Co., Ltd. Method for treating cancer
SG11201708286PA (en) 2015-04-20 2017-11-29 Epizyme Inc Combination therapy for treating cancer
EA201890009A1 (ru) 2015-06-10 2018-07-31 Эпизайм, Инк. Ингибиторы ezh2 для лечения лимфомы
CA2996412A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
WO2017132518A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
CA3025933A1 (en) * 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
EP3471830A4 (en) 2016-06-17 2020-02-26 Epizyme Inc EZH2 INHIBITORS TO TREAT CANCER
EP3532605A4 (en) 2016-10-26 2021-01-13 Sonic Master Limited ENHANCED GENERATION OF MUSCLE LINE CELLS AND THEIR THERAPEUTIC USES
KR101913693B1 (ko) * 2016-12-14 2018-10-31 사회복지법인 삼성생명공익재단 SS18-SSX 융합 유전자 특이적 siRNA 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
EP3630080A4 (en) * 2017-06-02 2021-03-10 Epizyme, Inc. USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
US11452727B2 (en) 2017-09-05 2022-09-27 Epizyme, Inc. Combination therapy for treating cancer
WO2019236957A1 (en) * 2018-06-07 2019-12-12 The Regents Of The University Of Michigan Prc1 inhibitors and methods of treatment therewith
WO2023159124A2 (en) * 2022-02-17 2023-08-24 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1036915A (en) 1911-05-25 1912-08-27 Joseph Schindler Utilizing exhaust-steam.
CN117534755A (zh) * 2005-05-09 2024-02-09 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
RU2765155C2 (ru) 2010-09-10 2022-01-26 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
AU2012223448B2 (en) 2011-02-28 2017-03-16 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
CA2867282C (en) * 2012-03-12 2024-04-02 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
KR20220123339A (ko) 2012-04-13 2022-09-06 에피자임, 인코포레이티드 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
JP6340361B2 (ja) * 2012-04-13 2018-06-06 エピザイム，インコーポレイティド がんを処置するための組合せ治療
RU2658919C2 (ru) * 2012-10-15 2018-06-26 Эпизайм, Инк. Замещенные бензольные соединения
NZ746054A (en) * 2012-10-15 2020-07-31 Epizyme Inc Methods of treating cancer
US20150313906A1 (en) * 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
WO2014100646A1 (en) * 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
US9701666B2 (en) 2012-12-21 2017-07-11 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
WO2014144747A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP2970281A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BENZENE COMPOUNDS
WO2015010078A2 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3022184B1 (en) 2013-07-19 2017-09-27 Epizyme, Inc. Substituted benzene compounds
FI3057962T3 (fi) 2013-10-16 2023-11-03 Epizyme Inc Hydrokloridisuolamuoto ezh2-estoon
EP3057594A4 (en) * 2013-10-18 2017-06-07 Epizyme, Inc. Method of treating cancer
EA201691079A1 (ru) * 2013-12-06 2017-03-31 Эпизим, Инк. Комбинированная терапия для лечения онкологического заболевания
MX2021007651A (es) * 2014-06-17 2021-08-11 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.
EP3160940A4 (en) 2014-06-25 2018-05-02 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
MX2021007003A (es) * 2014-10-16 2022-08-09 Epizyme Inc Método para tratar el cáncer.

Also Published As

Publication number Publication date
IL289947A (en) 2022-03-01
EA201790845A1 (ru) 2017-08-31
KR20170070140A (ko) 2017-06-21
JP2017532338A (ja) 2017-11-02
CA2963149A1 (en) 2016-04-21
JP2021105022A (ja) 2021-07-26
AU2015331729A1 (en) 2017-04-13
SG10201903356XA (en) 2019-05-30
CN112168967A (zh) 2021-01-05
EP3206688A4 (en) 2018-06-13
NZ730365A (en) 2024-03-22
WO2016061507A1 (en) 2016-04-21
JP2020097615A (ja) 2020-06-25
IL310279A (en) 2024-03-01
BR112017007738A2 (pt) 2018-01-30
MX2021007003A (es) 2022-08-09
AU2021200995A1 (en) 2021-03-11
US20160346293A1 (en) 2016-12-01
IL251411B (en) 2020-08-31
IL276545A (en) 2020-09-30
US10946024B2 (en) 2021-03-16
KR102397720B1 (ko) 2022-05-13
CN106794177A (zh) 2017-05-31
US9889138B2 (en) 2018-02-13
BR112017007738B1 (pt) 2023-04-11
US20180133224A1 (en) 2018-05-17
AU2022221580A1 (en) 2022-09-22
SG11201702488YA (en) 2017-04-27
IL251411A0 (en) 2017-05-29
US20210267990A1 (en) 2021-09-02
JP2023109922A (ja) 2023-08-08
EP3206688A1 (en) 2017-08-23
US20200009152A1 (en) 2020-01-09
US10369155B2 (en) 2019-08-06
IL276545B (en) 2022-02-01
IL289947B2 (en) 2024-06-01
IL289947B1 (en) 2024-02-01
AU2021200995B2 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
MX2017004969A (es) Metodo para tratar el cancer.
MX2022001757A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer.
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
MX2017001154A (es) Metodos y combinaciones terapeuticas para tratar tumores.
MX2019005465A (es) Metodo de tratamiento de un tumor inmunoterapeutico.
MX2022001120A (es) Inhibidor de pd-1 para usarse en el tratamiento de cancer de piel.
MX2018012132A (es) Reduccion de carga tumoral mediante administracion de antagonistas de ccr1 en combinacion con inhibidores de muerte-1 programada (pd-1) o inhibidores de ligando-1 de muerte-1 programada (pd-l1).
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
PH12015502075A1 (en) Treatment of cataplexy
MX2018004132A (es) Método de tratamiento de meduloblastoma con un inhibidor de ezh2.
MX2022013390A (es) Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto)/cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2.
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
MX2017001686A (es) Anticuerpos anti-ceramida.
NZ722600A (en) Methods of treating mild brain injury
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
PH12016502244A1 (en) Hsp70 modulators and methods for making and using the same
MX2019006694A (es) Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
MX2023003924A (es) Metodos de administracion de tratamiento antifibrotico.
WO2015134603A3 (en) Methods for treating cancer
NZ728612A (en) Treatment of androgen deprivation therapy associated symptoms
MX2019014291A (es) Metodo de tratamiento.
NZ725067A (en) Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer